Ipca Labs.

IPCALAB28 Mar 2024
Pharmaceuticals
+40.10 (+3.35%)
Lowest Today
Highest Today
Today’s Open
Prev. Close
52 Week High
52 Week Low
To Invest in Ipca Labs.
Ipca Labs.
Pharmaceuticals
IPCALAB28 Mar 2024
+40.10 (+3.35%)
1D
1M
6M
1Y
5Y
All

Ipca Labs. - Share Price & Details

Lowest Today
1200.65
Highest Today
1245
Today’s Open
1200.65
Prev. Close
1198.15
52 Week High
1264
52 Week Low
670
Traded Volume
Market Cap(Cr)
Avg Traded Price
1 Year return
56.49%
Upper Circuit
Lower Circuit
P/E TTM
57.06
P/B Ratio
5.06
Traded Value(Cr)
0.00
EPS TTM
21.7
Book value
Dividend
0.32%

Price Performance

5.54 %
1 Wk
4.27 %
1 M
12.89 %
3 M
56.49 %
1 Y
10.62 %
YTD

Traded Volume Movement

Technical Details

Support 3
1169
Support 2
1186
Support 1
1212
Pivot Point :
1229
Resistance 1
1255
Resistance 2
1271
Resistance 3
1297

Reports

Peer Comparison

Scrip NamePriceDaily ChangeM.Cap (Cr)1 Year Returns %P/E (TTM)PB Ratio
Ipca Laboratories Ltd
₹1,238.25(+40.10/3.35%)
1,238.25+40.1031,414.9256.4957.065.06
Cipla Ltd
₹1,494.65(+28.45/1.94%)
1,494.65+28.45120,672.8768.0236.704.66
Astrazeneca Pharma India Ltd
₹5,320.40(+0.65/0.01%)
5,320.40+0.6513,301.0059.2083.3920.31
Bliss GVS Pharma Ltd
₹112.65(-1.50/-1.31%)
112.65-1.501,179.3458.2617.281.21
Abbott India Ltd
₹26,946.00(+197.55/0.74%)
26,946.00+197.5557,260.2524.8049.9818.42
Amrutanjan Health Care Ltd
₹618.65(+7.45/1.22%)
618.65+7.451,788.564.1140.656.83

About Ipca Laboratories Ltd

Ipca Laboratories Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 31414.92 crores. It has reported a sales of Rs. 1506.83 crores and a net profit of Rs. 136.94 crores for the quarter ended December 2018. The company management includes Premchand Godha, Premchand Godha,A K Jain,Pranay Godha,Prashant Godha,Anand T Kusre,Manisha Premnath,Kamal Kishore Seth,Narendra Mairpady,Harish P Kamath (Ipca Laboratories Ltd) among others.
Chairman
Premchand Godha
Registered office
48 Kandivli Industrial Estate,Kandivli (West),Mumbai,Maharashtra,400067
FAX :91-22-28686613
Background
Incorporation Year1949
Face Value₹1
Market Lot1

Latest News

Stupendous FY24 drives market cap of 25 cos by Rs 1 lakh crore
A stellar run by domestic equities in FY24 saw the market capitalization of 25 companies rise by atleast Rs 1 lakh crore in a year. Of this, 17 of them are part of benchmark Nifty 50.The Nifty has gained nearly 29% in FY24 and it also tested a lifetime high after a muted show in FY23.Robust corporate earnings, high capital investments by the government, strong domestic economic growth.
29 Mar 2024 | 11:43 AM
Buy or sell: Rajesh Palviya of Axis Securities recommends to buy, hold?
Stock Market News: Domestic equity benchmark indices, the Sensex and Nifty 50, finished Thursday's session—the final trading day of the fiscal year 2024—with strong gains amidst favourable global cues. Nifty 50 zoomed around 30% in FY24, and Sensex surged about 28% in the same period. On Thursday, the 30-share BSE Sensex closed higher by 655.04 points or 0.90% at 73,651.35 level.
29 Mar 2024 | 11:02 AM
Short-term picks: Three stocks that may generate 17-25% returns
The Nifty 50 index has consistently displayed a bullish price structure, characterised by higher top, higher bottom formations, and is hovering near its all-time high levels on the monthly charts, indicating a strong positive sentiment for the long term. Recently, the index found significant support at the 13-week EMA (exponential moving average) and formed a notable Bullish Opening.
29 Mar 2024 | 10:01 AM
Three stocks to bet on for 17-25% return as bulls may rule Nifty
The Nifty 50 index has consistently displayed a bullish price structure, characterised by higher top, higher bottom formations, and is hovering near its all-time high levels on the monthly charts, indicating a strong positive sentiment for the long term. Recently, the index found significant support at the 13-week EMA (exponential moving average) and formed a notable Bullish Opening.
29 Mar 2024 | 11:07 AM
Buy or sell: Rajesh Palviya of Axis Securities recommends to buy, hold?
Stock Market News: Domestic equity benchmark indices, the Sensex and Nifty 50, finished Thursday's session—the final trading day of the fiscal year 2024—with strong gains amidst favourable global cues. Nifty 50 zoomed around 30% in FY24, and Sensex surged about 28% in the same period. On Thursday, the 30-share BSE Sensex closed higher by 655.04 points or 0.90% at 73,651.35 level.
29 Mar 2024 | 11:02 AM

How to buy Ipca Labs. shares on nse?

To buy Ipca Labs. shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Ipca Labs. share price today?

The Ipca Labs. shares price on nse is Rs.1238.25 today.

What is the market cap of Ipca Labs. shares on BSE ?

The company has a market capitalization of Rs.31414.92Cr

What is the PE & PB ratio of Ipca Labs. shares ?

PE is 57.06 and PB is 5.06

What is the 52 Week High and Low of Ipca Labs. shares?

Ipca Labs. stock price high: Rs.1264 Ipca Labs. stock price low: Rs.670

Is Ipca Labs a government-run institution?

No, IPCA Laboratories is not a government-run organization. It is a privately-owned pharmaceutical company based in India. IPCA Laboratories was founded in 1949 and has since grown to become one of the leading pharmaceutical companies in India.

Who is Ipca Labs’ owner?

IPCA Laboratories is a publicly-traded company and its ownership is spread among its shareholders. The Promoter of IPCA Labs is Mr. Premchand Godha and his family.

How well is Ipca Labs doing?

IPCA Laboratories operates in the pharmaceutical industry and has a diverse product portfolio that includes medicines for various therapeutic segments, including antimalarials, anti-bacterial, pain management, and cardiovascular drugs.

Ipca Labs’ consolidated revenue has gone from Rs. 3773.18 crores in March 2019 to  Rs. 5,829.79 crores on 31 March 2022. The net profit has gone from Rs. 443.03 crores to Rs. 910.95 crores in the same period.

Ipca Labs stock has given a positive return of 10.05% over the past three years and a negative return of -18.57% over the past one year.

 

What are the latest results of Ipca Labs?

The last fiscal result of Ipca Labs was declared in March 2022 and they reported a consolidated revenue of INR 5,829.79 crore and net profit of Rs. 910.95 crores.

What are the potential catalysts that positively impact the stock price of Ipca lab?

Some potential catalysts that may positively affect IPCA Laboratories' stock price could include:

  • Strong financial results
  • Expansion in new markets
  • Launch of new products
  • Regulatory approvals
  • Industry trends
setTimeout(function() { }, 5000);